Pieris Pharmaceuticals (PIRS)
(Delayed Data from NSDQ)
$17.07 USD
-0.13 (-0.76%)
Updated Sep 24, 2024 02:09 PM ET
After-Market: $17.20 +0.13 (0.76%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Pieris Pharmaceuticals, Inc. [PIRS]
Reports for Purchase
Showing records 21 - 40 ( 91 total )
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Chess Move Not Surprising; Year of Focus for ''060 and ''343; Target Increased to $9
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
KOL Day Shines Important Spotlight on PRS-060 and the New Excitement Around PRS-343
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q19 Results; Project Significant Boost in Pieris Visibility Over Near Term
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Welcome Back ?343; First Look at SITC Reignites I-O Franchise
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
First Real Look at PRS-343 Data Should Reignite Interest
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
PRS-060 Ready for Next Steps; Discussions With AstraZeneca Move Forward in Earnest
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
PRS-060 Continues Its Push Forward as Signals Remain Positive
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Eyes on Important Data Inflection Points in 2H19
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
First-In-Human PRS-060 Data Presented Setting Stage for Positive Future
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
First-In-Human PRS-060 Data Presented Setting Stage for Positive Future
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2018 Results; Upcoming Key Data in Both Respiratory and Oncology Programs
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q18 Results; Show Me Stage Increases on Promising Pipeline; Target Reduced to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
''343 Program Expands as Expected; Important Data Catalysts by Year End; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q18 Results; Driving Toward Inflection Points for Lead Assets; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Progress Update on Enrollment and Tumor Types for PRS-343 Ahead of 2H18 Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q18 Results; Upcoming PRS-343 Data Could Trigger Domino Effect in Developing 4-1BB Candidates
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J